Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Karyopharm Therapeutics Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.15
1.61
30.3
40.9
108
210
157
146
145
146
Research and development
86.9
107
161
122
151
161
149
139
143
126
Selling, general and administrative
24.9
48.8
105
126
144
145
132
115
105
General and administrative
23.9
24.9
48.8
Operating expenses
111
132
210
230
280
308
299
276
265
237
Operating income
-111
-131
-180
-189
-172
-98.3
-142
-130
-119
-90.7
Interest expense
2.49
15.6
27.1
26
25
23.8
37.4
45.8
Interest income
1.28
1.7
4.03
5.42
2.82
0.58
2.36
10.9
7.4
2.77
Other non-operating income
1.29
1.62
1.5
-10.3
-24.1
-25.5
-22.7
-13.2
43.1
-105
Pre-tax income
-109
-129
-178
-200
-196
-124
-165
-143
-76.4
-196
Income tax
0.14
0.06
0.03
0.04
0.31
0.27
0.37
0.32
0.06
0.04
Net income
-110
-129
-178
-200
-196
-124
-165
-143
-76.4
-196
EBITDA
-110
-130
-179
-188
-171
-97.5
-142
-129
-119
-90.4
EPS, basic
-43.89
-42.24
-47.20
-48.40
-40.89
-24.80
-30.36
-18.79
-9.41
-17.93
EPS, diluted
-43.89
-42.24
-47.20
-48.40
-40.89
-24.80
-30.36
-18.79
-14.00
-17.93
Shares, basic (weighted)
2.5
3.05
0
4.12
4.79
5
0.01
0.01
0.01
0.01
Shares, diluted (weighted)
2.5
3.05
0
4.12
4.79
5
0.01
0.01
0.01
0.01
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
49.7
69
118
129
85.9
190
135
52.2
62.5
60.5
Short-term investments
79.9
77.5
210
133
163
38.2
143
139
46.2
3.2
Receivables
7.86
12.9
22.5
47.1
27
30.8
26.2
Inventory
0.35
2.64
4.11
4.22
3.04
4.74
4.04
Other current assets
2.08
1.75
6.41
7.29
9.29
1.53
19.8
11.8
12.2
9.19
Total current assets
132
148
335
279
277
276
350
234
156
103
Property, plant and equipment
2.84
2.19
3.86
3.05
2.22
1.64
1.14
0.61
0.4
0.1
Lease right-of-use assets
10.6
9.36
7.92
6.24
4.28
5.88
4.55
Long-term investments
45.4
29.4
2
2.02
24.2
Total assets
180
180
341
295
313
305
358
240
164
108
Accounts payable
4.75
5.67
4.33
0.99
4.45
1.6
2.77
3.12
5.11
4
Accrued liabilities
11.4
21.4
32.5
40.9
52.9
69.1
58.4
61.4
60.7
64.5
Deferred revenue
21.9
9.36
2.34
0.3
Total current liabilities
16.5
49.5
46.9
46.4
60.2
73.7
65.9
69.5
92.3
92.1
Lease liabilities
13.2
11.3
8.97
6.1
2.79
6.71
5.74
Other non-current liabilities
0
0.98
2.43
11.1
Total liabilities
18.1
50.8
158
245
263
385
375
377
350
401
Total debt
169
Paid-in capital
529
625
857
923
1,120
1,099
1,328
1,351
1,378
1,466
Retained earnings
-366
-495
-674
-873
-1,070
-1,179
-1,344
-1,487
-1,563
-1,759
Other comprehensive income
-0.27
-0.22
-0.24
-0.04
0.52
0.19
-0.64
-0.16
-0.36
0.07
Shareholders' equity
162
129
183
49.8
50.5
-79.7
-16.7
-136
-186
-293
Total equity
162
129
183
49.8
50.5
-79.7
-16.7
-136
-186
-293
Total liabilities and equity
180
180
341
295
313
305
358
240
164
108
Shares outstanding
2.79
3.3
4.05
4.35
4.92
5.04
7.53
115
8.41
18.3
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-110
-129
-178
-200
-196
-124
-165
-143
-76.4
-196
Depreciation and amortization
0.72
0.71
0.74
0.97
0.97
0.79
0.62
0.53
0.34
0.3
Stock-based compensation
22.3
20.4
17.3
15.3
24.4
29.8
35.4
21.7
18.4
14.1
Deferred income tax
0
0
0
0
0
0
0
0
Change in receivables
-7.86
-5.02
-9.62
-5.08
20.1
-3.8
4.59
Change in inventory
-0.35
-2.63
-1.46
-0.12
1.18
-1.7
0.7
Change in payables
0.95
0.91
-1.38
-3.3
3.47
-2.85
1.17
0.35
1.98
-1.1
Cash from operations
-84.4
-73.7
-159
-191
-160
-107
-150
-92.7
-127
-75.4
Capital expenditures
-0.07
-0.06
-2.36
-0.21
-0.15
-0.21
-0.12
0
-0.14
0
Purchases of investments
-135
-98.4
-243
-178
-275
-45.2
-226
-159
-58.8
0
Sales and maturities of investments
159
116
Cash from investing
24.6
17.1
-108
78.5
-53.7
142
-104
7.94
95.5
43.4
Cash from financing
51.2
75.7
316
124
172
73.6
194
1.12
41.6
30
Exchange rate effect
-0.07
0.21
-0.08
0.02
0.27
-0.05
-0.49
-0.03
-0.01
0.02
Net change in cash
-8.7
19.3
49.3
12
-41.6
108
-60.6
-83.7
9.62
-1.92
Free cash flow
-84.5
-73.8
-161
-191
-160
-107
-150
-92.7
-128
-75.4
Interest paid
5.18
5.18
5.18
5.18
17.1
10.7
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.62 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-56.2%
Operating income / revenue.
EBITDA margin
-56.1%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-153.3%
Pre-tax income / revenue.
Net margin
-153.3%
Net income / revenue.
Operating cash flow margin
-44.6%
Cash from operations / revenue.
Return on assets (ROA)
-201.9%
Net income / average total assets.
R&D / revenue
82.5%
Research and development expense / revenue.
SG&A / revenue
69.6%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
7.9%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
0.1%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
0.6%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-2.4%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
6.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-34.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-32.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-19.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
29.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
26.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
-70.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.79x
Current assets / current liabilities.
Quick ratio
0.71x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.49x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$5,067.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$2,258.00
Cash from operations / diluted weighted shares.
Book value per share
-$14.56
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.25x
Market cap / revenue.
Earnings yield
-611.6%
Net income / market cap (the inverse of P/E).
What was Karyopharm Therapeutics Inc.'s revenue in fiscal 2025?
Karyopharm Therapeutics Inc. reported revenue of $146.1M for fiscal 2025, 0.6% higher than the year before.
Was Karyopharm Therapeutics Inc. profitable in fiscal 2025?
No. It reported a net loss of $196.0M.
How much free cash flow did Karyopharm Therapeutics Inc. generate in fiscal 2025?
Cash from operations of $75.4M minus capital expenditures of $0.0 left free cash flow of -$75.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.